Login to Your Account


DUBLIN – Early stage Swiss firm Memo Therapeutics AG raised CHF5 million (US$5 million) in a series A2 round to fund preclinical development of its antibody discovery platform, which is based on a proprietary method of capturing and banking an individual's antibody repertoire.

LONDON – The lessons of the Ebola epidemic have come together with a series of scientific advances, and expertise acquired over a lifetime in biotech, to inspire a novel vaccine technology that is designed to provide genus-wide protection against viral infections.

'A big learning curve'

Accelerator Life Science Partners has another startup under its wings, but the process to launch Proniras Corp. wasn't exactly your typical newco formation.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: